Medtronic saw 8.7% year over year growth in the third quarter of fiscal year 2026, according to financial results posted Feb. 17.
Five things to know:
1. Medtronic saw $9 billion in global revenue, and $4.5 billion in U.S. sales.
2. Neuroscience sales were $2.6 billion, a 2.5% increase year over year.
3. Cranial and spinal technologies saw 4.8% year over year growth with $1.3 billion. Specialty therapies and neuromodulation saw year-over-year growth of 1.9% and 5.8%, respectively.
4. Medical Surgical business revenue was $2.2 billion, a 4.9% increase year over year, and cardiovascular sales were $3.5 billion, a 13.8% jump. Diabetes revenue was $796 million, a 14.8% year over year increase.
5. Medtronic maintained its fiscal year 2026 guidance and expects 5.5% full-year growth.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.